HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial
DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next...
294 Views
Dr Reddy’s Laboratories Ltd - GRevlimid Revenue Topped Out
The US business reported sales of $391Mn (-3.0% QoQ), led by a lower base business of ~$245 Mn QoQ, gRevlimid ~$115 Mn QoQ, and acquisition...
303 Views
Dr Reddy’s Laboratories Ltd - Transition from Generic to Niche Company
North America to clock a 7% CAGR from FY24-26E driven by 25 new product launches in the generics segment (either FTFs or in the 1st wave),...
292 Views
Dr Reddy’s Laboratories Ltd - Stability in US and Indian Business
The US business reported sales of $410Mn (+5.5% QoQ), led by stable base business of ~$250 Mn QoQ, gRevlimid ~$120 Mn QoQ, and acquisition business...
288 Views
Pharmaceuticals: US Generic Growth to Stay, Selective on Structural Play
The pharmaceutical sector, emerging from the volatility of the past two post-pandemic and geopolitically tumultuous years, is now on a recovery...
277 Views